Solthis Solidarité Thérapeutique et Initiatives pour la Santé

Do not wait for the crisis to act

Donate now

Fighting HEPATITIS

hepatites

The 10th leading cause of death worldwide

Hepatitis B virus (HBV) is the tenth leading cause of death and the third leading cause of cancer worldwide.  It is estimated that more than 500 million people are infected worldwide. West and Central Africa is one of the most affected regions with nearly 10% of the population infected. The majority of people who develop complications from hepatitis B are infected in their first months of life.

In children under 5 years of age, in addition to mother-to-child transmission, horizontal transmission from infected individuals is important. The earlier the infection occurs, the greater the risk of chronic infection, leading to cirrhosis and cancer: 80-90% of infants infected during the first year of life and 30-50% of children infected before the age of 6 years will develop chronic infection (compared to less than 5% of healthy adults infected in adulthood).

Vaccine remains the key to fighting this infectious disease and the WHO recommends that all infants be vaccinated as soon as possible after birth, preferably within the first 24 hours. However, this recommendation is not yet widely implemented.

 

For example, in 2015, global coverage of the vaccine dose at birth was only 35%, with high coverage achieved only in the WHO regions of the Americas and the Western Pacific.

 

Our action: Strengthen advocacy, testing and vaccination against the virus at birth

In response to these needs, Solthis continues its advocacy work and also seeks to develop projects

  • while antiviral drugs are currently available to treat infected people, access to diagnosis and treatment of hepatitis B remains limited in many low-resource countries. For example, in 2015, only 9% of people infected with the hepatitis B virus were aware of their HIV status, and among diagnosed patients, global treatment coverage was only 8% (1.7 million).
  • and promote vaccination from birth (triple elimination)

Country action

MALINIGERGUINEASIERRA LEONE

Expertise

OPERATIONAL RESEARCHCAPACITY BUILDINGADVOCACY FOR FAIR ACCESS TO QUALTITY HEALTH CAREHUMAN RESOURCES FOR HEALTHSTRENGTHENING SYSTEMS AND HEALTH SERVICESHEALTH PRODUCTS AND PHARMACEUTICAL SYSTEMLABORATORIES AND TECHNICAL PLATFORMSHEALTH FINANCINGGOVERNANCE AND HEALTH POLICIESHEALTH INFORMATION SYSTEM

Health priority

Fighting HIV / AIDSFighting tuberculosisInfectious and emerging diseasesMALARIAFighting HEPATITISFighting Covid-19

Associated contents

Séroprévalence des virus de l’immunodéficience humaine et des hépatites B et C chez les donneurs de sang à Ségou au Mali

2012 |  Scientific Papers

MALIOPERATIONAL RESEARCHFighting HEPATITIS

Author(s) : M.C. Koné, E.T. Sidibé, K.K. Mallé, S. A. Beye, G. Lurton, M.T. Diarra Journal : Médecine et Santé Tropicales 2012; xx : 1-2. doi : 10.1684/mst.2012.0016

  DOI : 10.1684/mst.2012.0016

3rd Scientific Sessions – Niamey, October 2009

2009

NIGERADVOCACY FOR FAIR ACCESS TO QUALTITY HEALTH CARECAPACITY BUILDINGOPERATIONAL RESEARCHFighting HEPATITISFighting HIV / AIDSFighting tuberculosis

The Scientific Days, organized by the ULSS and CMT, in partnership with Solthis and GIP Esther, took place on 2 and 3 October 2009 in Niamey in the presence of Professor Katlama (Solthis President), Prof. Brucker (Treasurer Solthis and CEO of Esther) but also of Dr Kassi (Ivory Coast) and Professor Toure (Senegal). More than 250 physicians, health professionals, representatives of the fight against HIV, tuberculosis in Niger attended these days. Many topics on Chess therapeutic Opportunistic Infections, PMTCT, Accidents of exposure to blood and the delegation of tasks were discussed.

 

Our projects

gifSolthisGB-300x300

Stay informed

Stay informed about our projects and news from Solthis by subscribing to our newsletter.

S'inscrire

© Solthis 2021 - All rights reserved | Legal notice | Personal data | Cookie Management | Sitemap